

UCSF

UC San Francisco Previously Published Works

Title

Characterizing people who inject drugs with no history of opioid agonist therapy uptake in Iran: Results from a national bio-behavioural surveillance survey in 2020.

Permalink

<https://escholarship.org/uc/item/4fq1c8f6>

Journal

International Journal of Mental Health and Addiction, 22(4)

ISSN

1557-1874

Authors

Mehrabi, Fatemeh
Mehmandoost, Soheil
Mirzazadeh, Ali
[et al.](#)

Publication Date

2024-08-01

DOI

10.1007/s11469-022-00992-x

Peer reviewed



Published in final edited form as:

Int J Ment Health Addict. 2024 August ; 22(4): 2378–2390. doi:10.1007/s11469-022-00992-x.

Characterizing people who inject drugs with no history of opioid agonist therapy uptake in Iran: Results from a national bio-behavioural surveillance survey in 2020

Fatemeh Mehrabi¹, Soheil Mehmandoost¹, Ali Mirzazadeh², Alireza Noroozi³, Fatemeh Tavakoli¹, Hossein Mirzaei¹, Mehrdad Khezri¹, Ghazal Mousavian¹, Nima Ghalekhani¹, Parvin Afsar Kazerooni⁴, Fatemeh Navaiian⁵, Zahra Farajzadeh⁶, Mostafa Shokoohi¹, Hamid Sharifi¹, Mohammad Karamouzian^{1,7,8}

¹HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran

²Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA

³Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran

⁴Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

⁵Department of Control of Disease, Deputy of Health, Shahid Beheshti Medical University, Tehran, Iran

⁶Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

⁷Centre On Drug Policy Evaluation, Saint Michael's Hospital, Toronto, ON, Canada

⁸Brown School of Public Health, Brown University, Providence, RI, USA

Abstract

Injection drug use is the primary driver of the human immunodeficiency virus HIV epidemic in Iran. We characterized people who inject drugs (PWID) living in Iran who had never received opioid agonist therapy (OAT) and examined barriers to OAT uptake. We recruited 2,684 PWID with a history of drug injection in the previous 12 months using a respondent-driven sampling approach from 11 geographically dispersed cities in Iran. The primary outcome was no lifetime uptake history of OAT medications. The lifetime prevalence of no history of OAT uptake among PWID was 31.3%, with significant heterogeneities across different cities. In the multivariable analysis, younger age, high school education or above, no prior incarceration history, and shorter length of injecting career was significantly and positively associated with no history of OAT uptake. Individual-level barriers, financial barriers, and system-level barriers were the main barriers to receiving OAT. PWID continue to face preventable barriers to accessing OAT, which calls for revisiting the OAT provision in Iran.

Keywords

Harm reduction; Iran; Injection drug use; Opioid agonist therapy; Survey

INTRODUCTION

In several countries, including Iran, injection drug use continues to be the main driver of the HIV epidemic (Van Santen et al., 2021). In Iran, where about 340,000 people who inject drugs (PWID) live (Rastegari et al., 2022), the pooled prevalence of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) among PWID has been estimated to be 9.7% and 46.5%, respectively (Rahimi et al., 2020; Rajabi et al., 2021). Opioids are the most prevalent drugs in Iran among the general population (Mohebbi et al., 2019) and PWID (Nakhaeizadeh et al., 2020). Opium is the primary opioid of use in Iran, followed by *shireh* (i.e., refined opium), non-prescribed methadone, and heroin/heroin-kerack (i.e., a more potent form of street heroin that does not have any cocaine but contains heroin, codeine, morphine, and caffeine) (Amin-Esmaeili et al., 2016; Farhoudian et al., 2014).

Opioid agonist therapy (OAT) is regarded as an essential medication by the World Health Organization due to its crucial role in reducing heroin injection, injection-related morbidity and mortality, as well as reduction in crime rates (Gisev et al., 2019). Iran has scaled up its substance use treatment and harm reduction programs since the early 2000s, services that are predominantly tailored towards people with opioid use disorder (OUD). Indeed, Iran has the most extensive OAT program in the Eastern Mediterranean region, with over 7,500 clinics providing these services (Ekhtiari H, 2020). OAT programs continuously struggle to reach a balance between safe and effective treatment and optimal coverage that meets the needs of PWID. Given the favourable mental and physical health outcomes associated with uptake of appropriately dosed OAT among PWID (e.g., lower HIV and HCV acquisition risk, increased HIV testing, reduced fatal and non-fatal overdose, improved day-to-day functioning, reduced withdrawal symptoms, improved depressive symptoms, and improved quality of life) (Bahji et al., 2019; Ferraro et al., 2021; Moazen-Zadeh et al., 2021; Nielsen et al., 2016), characterizing OAT access among PWID is essential for informing harm reduction policies and planning.

While previous studies have tried to characterize people who have accessed OAT (Nakhaeizadeh et al., 2020), treatment uptake is suboptimal, and our understanding of PWID who are disconnected from substance use treatment services and have never received such services is minimal. Moreover, among PWID who have never been linked to substance use care and treatment, barriers to accessing OAT services remain to be studied. The objectives of our study were to i) measure the lifetime prevalence of no history of OAT uptake among PWID in Iran; and ii) identify the primary barriers to OAT uptake among PWID across the country. We hypothesized that access to OAT is inequitable across the country and certain socio-demographic and behavioural characteristics reduce PWID's access to OAT. The findings of this study might be used to improve the accessibility of OAT services and remove the barriers to using these services in Iran.

METHODS

Setting and sampling

Data were obtained from the recent nationwide integrated bio-behavioural surveillance survey (IBBSS) of PWID in Iran (July 2019 to March 2020). Details of the methodology are previously described (Khezri et al., 2021; Khezri et al., 2022).

In brief, data were collected using a structured and standard behavioural questionnaire via face-to-face interviews in 11 major cities. Participants were recruited using the respondent-driven (RDS) sampling method, a snowball sampling approach for researching hard-to-reach populations (Heckathorn, 1997). Participants were eligible if they were at least 18 years old, had at least one injection drug use practice in the last 12 months (assessed by self-report), had a valid coupon (except initial recruits, called “seeds”), and provided verbal consent. Initial recruitment was performed using a non-random selection of well-networked participants called “seeds”. Every seed was then provided with three referral coupons and trained to recruit up to three peers. Peers who had received a referral coupon had three weeks to participate before the coupon expired (Faghihi et al., 2021). This process was continued using the referral coupons until the intended sample size was reached.

Eligible participants completed a face-to-face structured interviewer-administered to answer a standardized validated risk assessment questionnaire developed based on recent IBBSS across various settings including USA, eight countries in Africa, Brazil, China and the Caribbean (Global Strategic Information, 2014). Using a standardized questionnaire allows for cross-country comparisons among PWID and helps better understand HIV dynamics among PWID. Following the translation of the questionnaire to Farsi, it was reviewed and revised based on feedback from a questionnaire working group, including local HIV and substance use experts at Iran’s Ministry of Health and key informants from the local community of PWID. The questionnaire took about an hour to complete and included several sections, such as PWID’s socio-demographic information, injection and non-injection substance use practices, sexual behaviours, substance use treatment history, HIV-related risks, mental health, and harm reduction service utilization. In addition, participants who consented to provide biological samples also completed a rapid test to assess their HIV (SD-Bioline, South Korea) and HCV serostatus. Those with reactive HIV tests completed a confirmatory test with Unigold HIV rapid test and were referred to voluntary counselling and testing services. Every participant received two United States Dollars (USD) as an incentive for completing the survey and HIV and HCV testing and one USD for each referred peer.

Outcome variable

Participants were asked whether they had ever received prescribed OAT medications (i.e., methadone, buprenorphine, or opium tincture maintenance treatment) at any point in life. Responses were coded as no vs. yes (reference group). To explore reasons for facing barriers in accessing OAT, participants were asked whether they had ever wanted to receive any OAT services but could not. Response options included “no, I have never wanted to seek OAT,” “yes, I wanted to receive OAT, and I received it,” and “yes, I wanted to, but I could

not.” People who reported being unable to receive OAT were further asked, “what were the reasons you could not receive the treatment?” with the following response options: the program was not free, there were no empty spots for new recruits to the treatment program, having a hard time and not feeling like getting treatment, could not afford the fees, no treatment program was available near my residence, mental health disorders, program’s service hours interfered with my work hours, not having an identification card which is required for signing up in the program, misbehaviours of staff and healthcare providers, and an opened-ended option for ‘other’ responses. Participants could choose multiple options.

Independent variables

Independent variables of interest were informed by Rhodes’ risk environment framework (Rhodes, 2009). Traditionally, research on substance use-related harms has primarily focused on individual-level risks and behaviour change. A growing body of evidence however, has highlighted the limitations of such conceptual frameworks (e.g., health belief model) that underscore individual-level decision-making interventions as a remedy to reducing substance use-related harms and adverse health outcomes (Rhodes, 2002; Strathdee et al., 2010). Rhodes’ framework takes on a more contextual approach towards identifying factors that affect PWUD’s health (Rhodes, 2002, 2009). Through the lens of Risk Environment Framework applied in this research, individual-level behaviours and outcomes (e.g., access to substance use treatment), are consequences or products of the interaction of individual-level factors (e.g., length of injecting career) with several influences within the economic (e.g., access to adequate regular income), physical (e.g., homelessness), political (e.g., drug laws and regulations), and social (e.g., relationship status) environments. Informed by this lens, the variables included in our analysis included socio-demographic and behavioural variables, including gender (man or woman), education (<high school, or high school), marital status (married or single), monthly income (USD 100+ or USD 100), homelessness history (yes or no), incarceration history (yes or no), length of injecting career (<1, or 1–5 years, or > 5 years), early (i.e., <18 years old) injection initiation (yes or no), and age at interview (continuous, per one year older).

Statistical analysis

We reported descriptive statistics and frequencies along with 95% confidence intervals (CI) for no history of OAT uptake and independent variables. To assess the correlates of no history of OAT uptake, bivariable and multivariable logistic regression models were constructed. Variables with a p-value <0.2 in the bivariable analysis were entered into the multivariable model, and the final model was selected via a backward elimination approach based on the smallest Akaike Information Criterion (AIC). Crude and adjusted odds ratio (aOR) along with 95% CI were reported. As unweighted regression models have been proposed to be more accurate, have more coverage, and provide more robust estimates than RDS-weighted models (Avery et al., 2019), we relied on an unweighted regression modelling approach which is indeed in line with an increasing body of evidence (Friedman et al., 2021; Saleem et al., 2021). As most substance use-related variables in the questionnaire had measured recent use/injection practices, they were not included in the regression analyses to avoid temporality bias. As a sensitivity analysis, we also reported RDS-adjusted estimates for the primary outcome and in subgroups of PWID.

We also categorized barriers to accessing OAT into three main themes. For the “other” response option, free texts were thematically summarized and, where consistent with the main themes, were included in the main themes. Responses that were not clarified in the free text or consistent with the main themes we reported as “other.” As the study was performed in different cities, we considered each city as a cluster and adjusted the cluster effects using Stata’s survey package. Data management and data analysis procedures were performed using Stata 14.2. RDS-adjusted estimates were calculated using RDS analyst 1.8–6.

Ethical considerations

Before starting the interview, participants were briefed about the study’s objectives and procedures and provided verbal informed consent. Interviews were conducted in a private room, and data were collected anonymously to ensure confidentiality. Participants’ refusal to participate in the study did not impact their access to healthcare services. The Research Ethics Board at the Kerman University of Medical Sciences reviewed and approved the study protocol and procedures (IR.KMU.REC.1397.573).

RESULTS

Participant characteristics

We analyzed data for 2,684 PWID with a lifetime history of opioid use (Table 1). Among them, 2564 (96.6%) were men, 1824 (69.1%) had <high school level of education, 655 (25.6%) were married, 1731 (66.1%) had a history of incarceration, 213 (8.4%) had injected for 1 year, and 561 (22.0%) had injected for 2–5 years. Moreover, 95.6% self-reported injecting opioids in the past three months. RDS-weighted and unweighted prevalence of socio-demographic variables are presented in Supplement 1.

Overall, the lifetime prevalence of no history of OAT uptake was 31.3% (95% CI: 29.5, 33.1). However, it varied greatly across the studied cities, ranging from 7.4% in East Azerbaijan to 63.1% in Lorestan (Figure 1). In the bivariable analysis, those who had never accessed OAT were significantly younger (Mean age: 38.5 vs. 41.0, p -value < 0.001), had high school education and above (36.9% vs. 28.8%, p -value < 0.001), had never been homeless (31.6% vs. 29.2%, p -value = 0.190), had never been incarcerated (31.6% vs. 29.2%, p -value < 0.001), and had a shorter injecting career (36.5% vs. 26.5%, p -value < 0.001). In the multivariable analysis (Table 2), the odds of never having received OAT were significantly and positively associated with lower age (aOR: 0.98; 95% CI: 0.97, 0.99), high school education or above (aOR: 1.39; 95% CI: 1.16, 1.67), no history of incarceration (aOR: 1.48; 95% CI: 1.23, 1.79), and shorter injecting career (aOR: 1.44; 95% CI: 1.06, 1.97).

Approximately 2,637 participants answered the question, “have you ever wanted to receive any OAT services but were unable to?” 1,352 (51.3%) of whom reported, “yes, I wanted to, but I could not.” People who reported being unable to receive OAT described the main underlying reasons, summarized thematically in Table 2. Individual-level barriers (e.g., having a hard time, mental health struggles): 914 (66.2%), financial barriers (e.g., unaffordable cost of OAT services): 257 (18.6%), and system-related barriers (e.g., service

availability interfering with working hours, long commute to OAT services, stigma and rejection from healthcare providers): 197 (14.3%) were the main three barriers to accessing OAT. Overall, 46 people reported “other” reasons, of which 34 people provided the free text, which was classified in the main themes, 12 (0.9%) participants reported the “other” response but did not specify further.

DISCUSSION

We found that one-third of PWID in Iran had never received OAT during their lifetime. While Iran benefits from the highest OAT coverage in the Eastern Mediterranean region, where less than ten countries provide OAT services (Roshanfekar et al., 2013), the observed gap and disparities in accessing OAT across the country are concerning. Younger people, those who had higher education, had never been incarcerated, and had a shorter injection career length had higher odds of no history of OAT uptake. About two-thirds of participants reported individual-level barriers, one-fifth reported financial issues, and more than one-tenth of participants reported system-related barriers in accessing OAT services.

Younger PWID were more likely to have never received OAT. This finding is consistent with an international body of evidence indicating several gaps in accessing OAT among young people (Pilarinos et al., 2021) and calls for revisiting and revising Iran’s national clinical OAT guidelines to further emphasize the need to improve OAT uptake for young PWID. While reduced access to OAT among young people is partly related to how OUD care and treatment are provided (Pilarinos et al., 2021), it could also be due to their lower perceived risks of opioid use, and higher levels of perceived or anticipated stigma towards receiving OAT (Earnshaw et al., 2019; Hadland et al., 2018). Substance-use stigma reduction interventions aimed at tackling stigma at the individual (e.g., acceptance and commitment therapy), societal (e.g., public awareness campaigns about OAT services), and structural levels (e.g., targeted educational programs for healthcare providers and law enforcement) could help lead to higher retention and better health outcomes among PWID and reduce interpersonal and structural stigma towards OAT uptake among them (Livingston et al., 2012; Woo et al., 2017).

No history of incarceration was associated with higher odds of no OAT uptake. This could be due to the provision of harm reduction services, including MMT inside prisons in Iran, which increases the odds of PWID’s access to OAT if incarcerated (Nakhaeizadeh et al., 2020). Ensuring that such services inside prisons are scaled up and receive continued support is essential, given their well-established effect on reduced injection- and non-injection-related harms as well as increased linkage to care both inside and outside prisons post-release (MacDonald, 1997; Marsden et al., 2017; Roshanfekar et al., 2013; Saberi Zafarghandi et al., 2021). We also noted that a lower duration of injecting career was associated with higher odds of no OAT uptake. Previous studies suggest that treatment-seeking practices are usually overlooked and postponed until serious complications emerge (Topp et al., 2008) and highlight the importance of providing low-threshold and accessible OAT services to facilitate access among people who are early injectors or are experimenting with injection drugs use (Montain et al., 2016).

Less than 4% of PWID in our study self-identified as women. Consistent with other parts of the world (El-Bassel & Strathdee, 2015), a minority of women—who are often socio-economically marginalized—inject drugs in Iran (Tavakoli et al., 2021). The most commonly used drug in Iran continues to be opium (4271/100000 people among men vs. 766/100000 among women) and the overall prevalence of substance use (injection or non-injection) has been estimated to be 5.23 times higher among men than women (Rastegari et al., 2022). In Iran, an estimated ~16000 women inject drugs (Nikfarjam et al., 2016) and ~3% of PWID are women (Dolan et al., 2011). While the low representation of women in our study could be reflective of the low prevalence of injection drug use among women, it could also be due to the high levels of stigma associated with injection drug use among women and potential adverse consequences for them in the conservative and traditional socio-cultural context of Iran (Dehghan et al., 2020; Sattler et al., 2021; Zolala et al., 2016).

More than half of the participants reported facing barriers to accessing OAT. PWID reported an array of individual, financial, and system-level barriers to accessing OAT services that could indeed be addressed through several scalable interventions. First, as personal struggles and challenges were frequently reported to complicate seeking OAT, existing services need to ensure that they are compatible with the long-term nature of recovery and continue supporting PWID despite their potentially repeated cycles of relapse (Wegman et al., 2017). It is also essential to ensure that existing OAT services are flexible and that a “one size fits all” approach is subject to limited success and would not work for everyone (Karamouzian et al., 2022). Second, the financial costs associated with accessing OAT care have been repeatedly reported as a significant barrier and need to be dealt with (Khazaei-Pool et al., 2018). OAT services in Iran are provided in public and private clinics with varying costs across different settings. While accurate estimates of the average cost of treatment in private settings are unclear, MMT would cost an average of ~\$20-\$30 per client/month in 2018 in public clinics. Notably, OAT services are also available at a lower cost in harm reduction drop-in centers which provide low-threshold services, but seeking services within those settings is often highly stigmatized (Hesam et al., 2014; Reza Davasaz Irani & Hasanpour, 2020). Moreover, health insurance for substance use treatment only covers clients with valid identification documents and merely a portion of monthly methadone or buprenorphine maintenance treatment packages (Momtazi et al., 2015). Lastly, system-level barriers could be addressed by cost-efficient interventions, such as revising the operational hours of OAT services, increasing accessibility of services in remote and rural areas, promoting gender-sensitive addiction care and treatment, and educating healthcare staff to ensure PWID do not face external stigma when seeking care (Dolan et al., 2011; Karamouzian et al., 2022; Shirley-Beavan et al., 2020). Future research in Iran should also investigate the barriers and facilitators to accessing OAT among PWID from the staff’s perspectives and ensure any programs aimed at improving these services are adequately informed by service providers’ input.

Limitations

We acknowledge the limitations of this study. First, the data was collected via self-reports which may be subject to recall and reporting biases. We tried to reduce probable biases by training local interviewers. Second, this cross-sectional study measured both exposure and

outcome at the same section of time; therefore, causality cannot be inferred. Lastly, men who inject drugs were overrepresented in the survey, limiting our findings' generalizability to women who inject drugs in Iran.

Conclusions

In summary, one-third of PWID had no history of OAT uptake. Although the increasing number of OAT services in Iran is encouraging, there is significant disparity across the country regarding accessing OAT. Moreover, several preventable barriers continue to undermine PWID's access to OAT and need to be addressed through revisiting and revising OAT-related policies and interventions.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

REFERENCES

- Alam-Mehrjerdi Z, Daneshmand R, Samiei M, Samadi R, Abdollahi M, & Dolan K. (2016). Women-only drug treatment services and needs in Iran: the first review of current literature. *DARU Journal of Pharmaceutical Sciences*, 24(1), 1–9. [PubMed: 26739353]
- Amin-Esmaili M, Rahimi-Movaghar A, Sharifi V, Hajebi A, Radgoodarzi R, Mojtabei R, Hefazi M, & Motevalian A. (2016). Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. *Addiction*, 111(10), 1836–1847. 10.1111/add.13453 [PubMed: 27177849]
- Avery L, Rotondi N, McKnight C, Firestone M, Smylie J, & Rotondi M. (2019). Unweighted regression models perform better than weighted regression techniques for respondent-driven sampling data: results from a simulation study. *BMC Medical Research Methodology*, 19(1), 1–13. [PubMed: 30611213]
- Bahji A, Cheng B, Gray S, & Stuart H. (2019). Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis. *The Acta Psychiatrica Scandinavica*, 140(4), 313–339. 10.1111/acps.13088 [PubMed: 31419306]
- Covington SS (2008). Women and addiction: A trauma-informed approach. *Journal of Psychoactive Drugs*, 40(sup5), 377–385.
- Dehghan M, Shokoohi M, Mokhtarabadi S, Tavakoli F, Iranpour A, Rad AAR, Nasiri N, Karamouzian M, & Sharifi H. (2020). HIV-related knowledge and stigma among the general population in the southeast of Iran. *Shiraz E Medical Journal*, 21(7), 1–8.
- Dolan K, Salimi S, Nassirimanesh B, Mohsenifar S, Allsop D, & Mokri A. (2011). Characteristics of Iranian women seeking drug treatment. *Journal of Women's Health*, 20(11), 1687–1691.
- Earnshaw VA, Bogart LM, Menino DD, Kelly JF, Chaudoir SR, Reed NM, & Levy S. (2019). Disclosure, stigma, and social support among young people receiving treatment for substance use disorders and their caregivers: a qualitative analysis. *International Journal of Mental Health and Addiction*, 17(6), 1535–1549. 10.1007/s11469-018-9930-8 [PubMed: 33312084]
- Ekhtiari H NA, Farhoudian A, Radfar SR, Hajebi A, Sefatian S, Zare-Bidoky M, Razaghi EM, Mokri A, Rahimi-Movaghar A, Rawson R. (2020). The evolution of addiction treatment and harm reduction programs in Iran: a chaotic response or a synergistic diversity. *Addiction*. Jul;115(7):1395–1403. 10.1111/add.14905 [PubMed: 31737965]
- El-Bassel N, & Strathdee SA (2015). Women who use or inject drugs: an action agenda for women-specific, multilevel and combination HIV prevention and research. *Journal of Acquired Immune Deficiency Syndromes* (1999), 69(Suppl 2), S182. [PubMed: 25978486]
- Faghihi SH, Ghalekhani N, Kazerooni PA, & Nasirian M. (2021). Size estimation of people who inject drugs and their geographical distribution in dogonbadan, Iran, during 2018: a mapping method. *International Journal of Mental Health and Addiction*, 1–13.

- Farhoudian A, Sadeghi M, Khoddami Vishteh HR, Moazen B, Fekri M, & Rahimi Movaghar A. (2014). Component analysis of Iranian crack; a newly abused narcotic substance in Iran. *Iranian journal of pharmaceutical research*, 13(1), 337–344. [PubMed: 24734089]
- Ferraro CF, Stewart DE, Grebely J, Tran LT, Zhou S, Puca C, Hajarizadeh B, Larney S, Santo T Jr, & Higgins JP (2021). Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. *Addiction*, 116(7), 1664–1676. [PubMed: 33140543]
- Friedman J, Syvertsen JL, Bourgois P, Bui A, Beletsky L, & Pollini R. (2021). Intersectional structural vulnerability to abusive policing among people who inject drugs: a mixed methods assessment in California's central Valley. *International Journal of Drug Policy*, 87, 102981.
- Gisev N, Bharat C, Larney S, Dobbins T, Weatherburn D, Hickman M, Farrell M, & Degenhardt L. (2019). The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. *The Lancet Public Health*, 4(7), e334–e342. [PubMed: 31201133]
- Hadland SE, Park TW, & Bagley SM (2018). Stigma associated with medication treatment for young adults with opioid use disorder: a case series. *Addiction Science & Clinical Practice*, 13(1), 15. 10.1186/s13722-018-0116-2 [PubMed: 29730987]
- Heckathorn DD (1997). Respondent-driven sampling: a new approach to the study of hidden populations. *Social problems*, 44(2), 174–199.
- Hesam S, Honarvar N, & Vahdat S. (2014). The analysis of cost-effectiveness of methadone and buprenorphine maintenance treatment for preventing HIV infection in drug-injection users (a case study: the selected withdrawal centers under the supervision of Shiraz University of Medical Sciences). *Journal of Health Accounting*, 3(3), 18–39.
- Hien D, Kropp F, Wells EA, Campbell A, Hatch-Maillette M, Hodgkins C, Killeen T, Lopez-Castro T, Morgan-Lopez A, & Ruglass LM (2020). The “women and trauma” study and its national impact on advancing trauma specific approaches in community substance use treatment and research. *Journal of Substance Abuse Treatment*, 112, 12–17.
- Huang LN, Flatow R, Biggs T, Afayee S, Smith K, Clark T, & Blake M. (2014). SAMHSA's concept of trauma and guidance for a trauma-informed approach.
- Global Strategic Information. (2014). Toolbox for conducting integrated HIV bio-behavioral surveillance (IBBS) in key populations: PWID questionnaire. <https://globalhealthsciences.ucsf.edu/sites/globalhealthsciences.ucsf.edu/files/ibbs-intro.pdf>
- Karamouzian M, Pilarinos A, Hayashi K, Buxton JA, & Kerr T. (2022). Latent patterns of polysubstance use among people who use opioids: A systematic review. *International Journal of Drug Policy*, 102, 103584.
- Khazae-Pool M, Moeeni M, Ponnet K, Fallahi A, Jahangiri L, & Pashaei T. (2018). Perceived barriers to methadone maintenance treatment among Iranian opioid users. *International Journal for Equity in Health*, 17(1), 1–10. [PubMed: 29301537]
- Khezri M, Karamouzian M, Sharifi H, Ghalekhani N, Tavakoli F, Mehmandoost S, Mehrabi F, Pedarzadeh M, Nejat M, & Noroozi A. (2021). Willingness to utilize supervised injection facilities among people who inject drugs in Iran: Findings from 2020 national HIV bio-behavioral surveillance survey. *International Journal of Drug Policy*, 97, 103355.
- Khezri M, Shokoohi M, Mirzazadeh A, Tavakoli F, Ghalekhani N, Mousavian G, Mehmandoost S, Kazerooni PA, Haghdoost AA, & Karamouzian M. (2022). HIV prevalence and related behaviors among people who inject drugs in Iran from 2010 to 2020. *AIDS and Behavior*, 1–13.
- Livingston JD, Milne T, Fang ML, & Amari E. (2012). The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. *Addiction*, 107(1), 39–50.
- MacDonald M. (1997). Mandatory drug testing in prisons. Centre for Research into Quality and Department of Sociology, University of Central England in Birmingham. https://www.iprt.ie/site/assets/files/5994/mandatory_drug_testing__morag_macdonald.pdf
- Marsden J, Stillwell G, Jones H, Cooper A, Eastwood B, Farrell M, Lowden T, Maddalena N, Metcalfe C, & Shaw J. (2017). Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. *Addiction*, 112(8), 1408–1418. [PubMed: 28160345]

- Moazen-Zadeh E, Ziafat K, Yazdani K, Kamel MM, Wong JSH, Modabbernia A, Blanken P, Verthein U, Schütz CG, Jang K, Akhondzadeh S, & Krausz RM (2021). Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials. *American Journal of Drug and Alcohol Abuse*, 47(3), 280–304. 10.1080/00952990.2021.1887202 [PubMed: 33780647]
- Mohebbi E, Haghdoost AA, Noroozi A, Vardanjani HM, Hajebi A, Nikbakht R, Mehrabi M, Kermani AJ, Salemianpour M, & Baneshi MR (2019). Awareness and attitude towards opioid and stimulant use and lifetime prevalence of the drugs: a study in 5 large cities of Iran. *International Journal of Health Policy and Management*, 8(4), 222. [PubMed: 31050967]
- Montazi S, Noroozi A, & Rawson R. (2015). An overview of Iran drug treatment and harm reduction programs. *Textbook of addiction treatment: international perspectives*. Springer, 543–554. 10.1007/978-88-470-5322-9_25
- Mountain J, Ti L, Hayashi K, Nguyen P, Wood E, & Kerr T. (2016). Impact of length of injecting career on HIV incidence among people who inject drugs. *Addictive Behavior*, 58, 90–94.
- Nakhaeizadeh M, Abdolahinia Z, Sharifi H, Mirzazadeh A, Haghdoost AA, Shokoohi M, Baral S, Karamouzian M, & Shahesmaeili A. (2020). Opioid agonist therapy uptake among people who inject drugs: the findings of two consecutive bio-behavioral surveillance surveys in Iran. *Harm Reduction Journal*, 17(1), 1–8. [PubMed: 31906957]
- Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, & Lintzeris N. (2016). Opioid agonist treatment for pharmaceutical opioid dependent people. *The Cochrane Database of Systematic Reviews* (5), Cd011117. 10.1002/14651858.CD011117.pub2
- Nikfarjam A, Shokoohi M, Shahesmaeili A, Haghdoost AA, Baneshi MR, Haji-Maghsoudi S, Rastegari A, Nasehi AA, Memaryan N, & Tarjoman T. (2016). National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran. *International Journal of Drug Policy*, 31, 147–152. [PubMed: 26980349]
- Pilarinos A, Bromberg DJ, & Karamouzian M. (2021). Access to medications for opioid use disorder and associated factors among adolescents and young adults: a systematic review. *JAMA Pediatrics*.
- Rahimi Y, Gholami J, Amin-Esmaeili M, Fotouhi A, Rafiemanesh H, Shadloo B, & Rahimi-Movaghar A. (2020). HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis. *Addiction*, 115(4), 605–622. [PubMed: 31631425]
- Rajabi A, Sharafi H, & Alavian SM (2021). Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis. *Harm Reduction Journal*, 18(1), 1–25. [PubMed: 33407500]
- Rastegari A, Baneshi MR, Hajebi A, Haghdoost AA, Sharifi H, Noroozi A, Karamouzian M, Shokoohi M, Mirzazadeh A, & Haji Maghsoudi S. (2022). Population size estimation of people using illicit drugs and alcohol in Iran (2015–2016). *International journal of health policy and management*.
- Reza Davasaz Irani, & Hasanpour S. (2020). Harm reduction programs in drop-in centers. *Medical Journal of Mashhad University of Medical Sciences*. 31(106), 28–31.
- Rhodes T. (2002). The ‘risk environment’: a framework for understanding and reducing drug-related harm. *International Journal of Drug Policy*, 13(2), 85–94.
- Rhodes T. (2009). Risk environments and drug harms: a social science for harm reduction approach. *International Journal of Drug Policy*, 20(3):193–201. Doi: 10.1016/j.drugpo.2008.10.003 [PubMed: 19147339]
- Robinson K, & Ickowicz S. Research with women who use drugs: applying a trauma-informed framework. *Journal of Addiction Medicine*, 10.1097.
- Roshanfekr P, Farnia M, & Dejman M. (2013). The effectiveness of harm reduction programs in seven prisons of Iran. *Iranian Journal of Public Health*, 42(12), 1430–1437. <https://pubmed.ncbi.nlm.nih.gov/26060645> [PubMed: 26060645]
- Saberi Zafarghandi MB, Eshrati S, Arezoomandan R, Farnia M, Mohammadi H, Vahed N, Javaheri A, Amini M, & Heidari S. (2021). Review, documentation, assessment of treatment, and harm reduction programs of substance use disorder in Iranian Prisons. *Iranian Journal of Public Health*, 27(1), 48–63.

- Saleem HT, Likindikoki S, Nonyane BA, Nkya IH, Zhang L, Mbwambo J, & Latkin C. (2021). Correlates of non-fatal, opioid overdose among women who use opioids in Dar es Salaam, Tanzania. *Drug and Alcohol Dependence*, 218, 108419.
- Sattler S, Zolala F, Baneshi MR, Ghasemi J, & Amirzadeh Googhari S. (2021). Public stigma toward female and male opium and heroin users. An experimental test of attribution theory and the familiarity hypothesis. *Frontiers in Public Health*, 9, 652876.
- Shirley-Beavan S, Roig A, Burke-Shyne N, Daniels C, & Csak R. (2020). Women and barriers to harm reduction services: a literature review and initial findings from a qualitative study in Barcelona, Spain. *Harm reduction journal*, 17(1), 1–13. [PubMed: 31906957]
- Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, & Hankins CA (2010). HIV and risk environment for injecting drug users: the past, present, and future. *The Lancet*, 376(9737), 268–284.
- Tavakoli F, Khezri M, Tam M, Bazrafshan A, Sharifi H, & Shokoohi M. (2021). Injection and non-injection drug use among female sex workers in Iran: a systematic review and meta-analysis. *Drug and Alcohol Dependence*, 221, 108655.
- Tavakoli M, Mohammadi L, Yarmohammadi M, Farhoudian A, Ja'fari F, & Farhadi MH (2014). Status and trend of substance abuse and dependence among Iranian women. *Archives of Rehabilitation*, 14, 30–37.
- Topp L, Iversen J, Conroy A, Salmon AM, Maher L, & NSPs C. o. A. (2008). Prevalence and predictors of injecting-related injury and disease among clients of Australia's needle and syringe programs. *Australian and New Zealand Journal of Public Health*, 32(1), 34–37. [PubMed: 18290911]
- Van Santen DK, Boyd A, Matser A, Maher L, Hickman M, Lodi S, & Prins M. (2021). The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: findings from an emulated target trial. *Addiction*.
- Wegman MP, Altice FL, Kaur S, Rajandaran V, Osornprasop S, Wilson D, Wilson DP, & Kamarulzaman A. (2017). Relapse to opioid use in opioid-dependent individuals released from compulsory drug detention centres compared with those from voluntary methadone treatment centres in Malaysia: a two-arm, prospective observational study. *Lancet Glob Health*, 5(2), e198–e207. [PubMed: 27964869]
- Woo J, Bhalerao A, Bawor M, Bhatt M, Dennis B, Mouravska N, Zielinski L, & Samaan Z. (2017). "Don't judge a book by its cover": A qualitative study of methadone patients' experiences of stigma. *Substance Abuse: Research and Treatment*, 11.
- Zelenev A, Shea P, Mazhnaya A, Rozanova J, Madden L, Marcus R, & Altice FL (2018). Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. *Drug and Alcohol Dependence*, 190, 82–88. [PubMed: 29990648]
- Zolala F, Mahdavian M, Haghdoost AA, & Karamouzian M. (2016). Pathways to addiction: a gender-based study on drug use in a triangular clinic and drop-in center, Kerman, Iran. *International Journal of High-Risk Behaviors & Addiction*, 5(2).




Figure 1. Percentage of people who never received OAT in different cities of Iran in the 2019–2020 national bio-behavioral surveillance survey.

Table1.

Bivariable logistic regression analysis to identify correlates of never opioid agonist therapy uptake among people who inject drugs in Iran, 2019– 2020.

Variables	Total	No history of OAT uptake			P-value
		n (%)	Crude OR	95% CI	
Overall	2684	839 (31.3)		29.50, 33.05	
Age at interview (year)	2631	38.5 (9.8) ¹	0.97	0.96, 0.98	<0.001
Gender					
Women	90 (3.4)	32 (35.6)	1.27	0.82, 1.97	0.287
Men	2564 (96.6)	777 (30.3)	1		
Education					
High school or above	814 (30.9)	300 (36.9)	1.54	1.29, 1.83	<0.001
Less than high school	1824 (69.1)	501 (28.8)	1		
Marital status					
Married	655 (25.6)	203 (31.0)	1.02	0.84, 1.24	0.817
Single	1901 (74.4)	580 (30.5)	1		
Monthly income					
<100 USD ²	1357 (52.7)	404 (29.8)	1.04	0.88, 1.22	0.668
100 USD	1220 (47.3)	354 (29.0)	1		
Homelessness history					
Never	1143 (43.4)	361 (31.6)	1.12	0.95, 1.31	0.190
Ever	1489 (56.6)	435 (29.2)	1		
Incarceration history					
Never	889 (33.9)	341 (38.4)	1.76	1.48, 2.09	<0.001
Ever	1731 (66.1)	452 (26.1)	1		
Duration of injection					
1 year	213 (8.4)	89 (41.8)	1.99	1.49, 2.66	<0.001
2–5 years	561 (22.0)	205 (36.5)	1.60	1.31, 1.95	<0.001
> 5 years	1775 (69.6)	470 (26.5)	1		
Early injection initiation (<18 years old)					
No	2473 (96.4)	744 (30.1)	1.05	0.66, 1.66	0.828
Yes	93 (3.6)	27 (29.0)	1		

¹Mean (SD)

²United States dollar

Table 2.

Barriers relating to OAT uptake in Iran in 2019 national bio-behavioural surveillance survey.

Barriers of OAT uptake	n (%)^I
Individual-level barriers (e.g., having a hard time, mental health problems)	914 (66.2)
Financial barriers (e.g., unaffordable cost of OAT services)	257 (18.6)
System-related barriers (e.g., service availability interfering with working hours, long distance to OAT services, stigma and rejection from healthcare providers)	197 (14.3)
Other reasons (not specified)	12 (0.9)

^IParticipants could report multiple reasons.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3.

Multivariable logistic regression analysis to identify correlates of never receiving opioid agonist therapy among people who inject drugs in Iran, 2019–2020

Variables	No history of OAT uptake		P-value
	Adjusted OR	95% CI	
Age at interview (year)	0.98	0.97, 0.99	0.001
Education			
High school or above	1.39	1.16, 1.67	<0.001
Less than high school	1		
Incarceration history			
Never	1.48	1.23, 1.79	<0.001
Ever	1		
Duration of injection			
1 year	1.44	1.06, 1.97	0.021
2–5 years	1.27	1.02, 1.59	0.030
> 5 years	1		

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript